Skip to main content
. 2022 Dec 23;10(12):e005224. doi: 10.1136/jitc-2022-005224

Figure 2.

Figure 2

Progression-free survival based on investigator assessment per immune-related response criteria among (A) all treated patients and (B) patients who had progressed on prior anti-PD-1 therapy. Median progression-free survival was 8.3 months (95% CI 3.4 months to not reached) in patients with no prior anti-PD-1 therapy. anti-PD-1, antiprogrammed death 1.